scholarly journals The peroxisome proliferator-activated receptor agonist pioglitazone and 5-lipoxygenase inhibitor zileuton have no effect on lung inflammation in healthy volunteers by positron emission tomography in a single-blind placebo-controlled cohort study

PLoS ONE ◽  
2018 ◽  
Vol 13 (2) ◽  
pp. e0191783 ◽  
Author(s):  
Delphine L. Chen ◽  
Howard J. Huang ◽  
Derek E. Byers ◽  
Adrian Shifren ◽  
Bryan Belikoff ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Cohort Study ◽  
Lung Inflammation ◽  
Receptor Agonist ◽  
Emission Tomography ◽  
Peroxisome Proliferator ◽  
Lipoxygenase Inhibitor ◽  
Peroxisome Proliferator Activated Receptor ◽  
Positron Emission ◽  
Single Blind

scholarly journals A diagnostic cohort study on the accuracy of 18-fluorodeoxyglucose (18FDG) positron emission tomography (PET)-CT for evaluation of malignancy in anterior mediastinal lesions: the DECiMaL study

BMJ Open ◽  
2018 ◽  
Vol 8 (2) ◽  
pp. e019471 ◽  
Author(s):  
Chiara Proli ◽  
Paulo De Sousa ◽  
Simon Jordan ◽  
Vladimir Anikin ◽  
Anand Devaraj ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Cohort Study ◽  
Fdg Pet ◽  
Malignant Disease ◽  
Mediastinal Mass ◽  
Emission Tomography ◽  
Secondary Outcome ◽  
Anterior Mediastinal Mass ◽  
Positron Emission ◽  
Pet Ct

ObjectivesThe aim of this study is to collate multi-institutional data to determine the value by defining the diagnostic performance of fluorodeoxyglucose positron emission tomography (FDG PET)/CT for malignancy in patients undergoing surgery with an anterior mediastinal mass in order to ascertain the clinical utility of PET/CT to differentiate malignant from benign aetiologies in patients presenting with an anterior mediastinal massSettingDECiMaL Study is a multicentre, retrospective, collaborative cohort study in seven UK surgical sites.ParticipantsBetween January 2002 and June 2015, a total of 134 patients were submitted with a mean age (SD) of 55 years (16) of which 69 (51%) were men. We included all patients undergoing surgery who presented with an anterior mediastinal mass and underwent PET/CT. PET/CT was considered positive for any reported avidity as stated in the official report and the reference was the resected specimen reported by histopathology using WHO criteria.Primary and secondary outcome measuresSensitivity, specificity, positive and negative predicted values of [18F]-FDG PET in determining malignant aetiology for an anterior mediastinal mass.ResultsThe sensitivity and specificity of PET/CT to correctly classify malignant disease were 83% (95% CI 74 to 89) and 58% (95% CI 37 to 78). The positive and negative predictive values were 90% (95% CI 83% to 95%) and 42% (95% CI 26% to 61%).ConclusionsThe results of our study suggest reasonable sensitivity but no specificity implying that a negative PET/CT is useful to rule out the diagnosis of malignant disease whereas a positive result has no value in the discrimination between malignant and benign diseases of the anterior mediastinum.

Sign in / Sign up

Export Citation Format

Share Document